Highlights of weekly biotech stock moves

BioSante Pharmaceuticals Inc. (NASDAQ:BPAX) gained $0.21 (27%) to $0.97 on Wednesday after FDA approved an NDA from partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) for Bio-T-Gel to treat male hypogonadism. BioSante is eligible for milestones and royalties upon commercialization of the transdermal testosterone gel.

BioSante was off $0.06 to $0.79 on the week. Teva, which gained $0.49 to $44.65 last week, also reported 4Q11 earnings (see "EPS Watch," A19)...